BLA 208673 · Sanofi-Aventis US
Soliqua 100/33
Insulin Glargine, Lixisenatide · Subcutaneous · Insulin Analog; GLP-1 Receptor Agonist
Priority reviewLast checked: Nov 20, 2026Latest source record: Mar 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Nov 21, 2016
Approved uses
2
Original approval plus efficacy supplements
Registered trials
679
239 Phase 3, 12 recruiting
FAERS reports
3,660
655 serious, 42 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 18, 2026.
SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. SOLIQUA 100/33 is a combination of insulin glargine, an insulin analog, and lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use ( 1 ) : Concomitant use in combination with any other product containing a GLP-1 receptor agonist is not recommended. Not recommended for the treatment of diabetic ketoacidosis. Has not been studied in combination with prandial insulin. Limitations of Use : SOLIQUA 100/33 contains lixisenatide. Coadministration with any other product containing lixisenatide or another glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended [see Warnings and Precautions (5.5) ] . SOLIQUA 100/33 is not recommended for the treatment of diabetic ketoacidosis. SOLIQUA 100/33 has not been studied in combination with prandial insulin.
Mechanism: SOLIQUA 100/33 SOLIQUA 100/33 is a combination of insulin glargine, a basal insulin analog, and lixisenatide, a GLP-1 receptor agonist. Insulin glargine The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analogs lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis and enhances protein synthesis. Lixisenatide Lixisenatide is a GLP-1 receptor agonist that increases glucose-dependent insulin...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 27, 2019 Supplement 7 · Efficacy LabelLetter
- Nov 21, 2016 Original approval · Type 4 - New Combination · priority review LetterLabelSummary Review
1 products under this application
- SOLIQUA 100/33 · INSULIN GLARGINE 300 UNITS/3ML; LIXISENATIDE 99MCG/3ML (100 UNITS/ML · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Glargine" as an intervention, any sponsor and status, largest first.
- The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00069784 · 12,537 participants · Start Aug 2003 · Primary completion Dec 2011
Drug: insulin glargine (HOE901); omega-3 polyunsaturated fatty acids (PUFA) and 1 more · For: Diabetes Mellitus, Non-Insulin-Dependent
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Cove, Australia · 40 sites in all
- Action to Control Cardiovascular Risk in Diabetes (ACCORD)Pivotal-lookingCompleted
National Heart, Lung, and Blood Institute (NHLBI)NIH
NCT00000620 · 10,251 participants · Start Sep 1999 · Primary completion Jun 2009
Drug: Anti-hyperglycemic Agents; Anti-hypertensive Agents and 1 more · For: Atherosclerosis; Cardiovascular Diseases; Hypercholesterolemia and 4 more
Sites: Minneapolis, Minnesota; New York, New York; Winston-Salem, North Carolina · 7 sites in all
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 DiabetesPivotal-lookingCompleted
GRADE Study GroupAcademic, hospital or other
NCT01794143 · 7,850 participants · Start May 2013 · Primary completion Apr 30, 2021
Drug: Sulfonylurea (glimepiride); DPP-4 inhibitor (sitagliptin) and 2 more · For: Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications
Sites: Birmingham, Alabama; Phoenix, Arizona; San Diego, California · 36 sites in all
- A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular EventsPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01959529 · 7,637 participants · Start Oct 29, 2013 · Primary completion Oct 16, 2016
Drug: insulin degludec; insulin glargine · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Montgomery, Alabama; Gilbert, Arizona · 446 sites in all
- A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes MellitusPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00399724 · 7,376 participants · Start Mar 2002 · Primary completion Aug 2003
Drug: Insulin glargine · For: Diabetes Mellitus, Type 2
- Glycemic Optimization Treatment StudyPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00552370 · 5,062 participants · Start Mar 2003 · Primary completion Mar 2005
Drug: Lantus® · For: Diabetes Mellitus, Type 2
- An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical PracticePivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00576368 · 4,464 participants · Start Jun 2003
Drug: INSULIN GLARGINE · For: Diabetes Mellitus
Sites: Brussels, Belgium
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT02451137 · 3,304 participants · Start Jun 16, 2015 · Primary completion Mar 2, 2018
Drug: Insulin glargine, 300 U/ml; Insulin glargine, 100 U/ml and 2 more · For: Diabetes Mellitus, Type 2
Sites: Birmingham, Alabama; Gulf Shores, Alabama; Guntersville, Alabama · 427 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased467
- product storage error402
- off label use355
- accidental exposure to product340
- exposure via skin contact203
- nausea154
- inappropriate schedule of product administration149
- visual impairment146
- drug ineffective123
- blood glucose decreased100
- device issue99
- diarrhoea80
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2017 | 222 |
| 2018 | 330 |
| 2019 | 316 |
| 2020 | 336 |
| 2021 | 388 |
| 2022 | 458 |
| 2023 | 414 |
| 2024 | 400 |
| 2025 | 457 |
| 2026 | 338 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Soliqua 100-33 (Insulin Glargine/Lixisenatide)
2024 spending
$300M
Beneficiaries
59,472
273,407 claims
Per beneficiary
$5,048
$56.01 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $121,393,843 |
| 2021 | $165,620,858 |
| 2022 | $215,943,202 |
| 2023 | $302,998,642 |
| 2024 | $300,185,496 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.
Andreadis P, Karagiannis T, Malandris K, et al. · Diabetes Obes Metab 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
Zeng Q, Xu J, Mu X, et al. · Front Endocrinol (Lausanne) 2023 · Meta-Analysis, Systematic Review
- More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
Rosenstock J, Cheng A, Ritzel R, et al. · Diabetes Care 2018 · Comparative Study, Randomized Controlled Trial
- Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial.
Kellerer M, Kaltoft MS, Lawson J, et al. · Diabetes Obes Metab 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial.
Thammakosol K, Sriphrapradang C · Diabetes Obes Metab 2023 · Randomized Controlled Trial
- A Randomized Controlled Trial on the Effect of Local Insulin Glargine on Venous Ulcer Healing.
Martínez-Jiménez MA, Kolosovas-Machuca S, Alcocer F, et al. · J Surg Res 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.